Wound Care Biologics Market By Product (Biological Skin Substitutes, Topical Agents), By Wound Type (Acute Wound, Chronic Wound), By End User (Hospitals and Clinics, Wound Centers and Burn Centers, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

Wound Care Biologics Market

The Wound Care Biologics Market is likely to experience a significant growth rate of 6.1% from 2023-2032 owing to increase in demand for wound care biologics and increase in research and developmwnt activites from pharmaceutical sector – .  Wound care biologics refers to development and production of advanced therapeutic products derived from living organisms or their components. These biologic products are specifically designed to promote wound healing, tissue regeneration, and the management of complex or chronic wounds. Wound care biologic products enable faster healing due to their efficiency & effectiveness in managing wounds.   

Key factors driving the growth of the wound care biologics market include the rise in burden of burn injuries such as road accidents, sport injuries, burn accidents, and trauma events, fosters the demand for wound care biologics products such as gels, ointments and creams, and skin substitutes. In addition, an increase in incidences of chronic diseases such as diabetes, rise in incidence of burn injury, and the surge in prevalence of chronic wounds such as foot ulcers, are expected to drive the growth of the wound care biologics market. Futhermore, the rise in geriatric population and it is a significant risk factor for diseases drive the market growth. The aging population is prone to chronic wounds due to age related factors. Rise in geriatric population led to increase in demand for wound care biologics to promote faster and more effective wound healing. 

Moreover, ongoing advancements in wound care management propel market growth. In addition, bioengineered skin substitutes are innovative products that are used in ulcer treatment to promote wound healing. These substitutes consist of living cells, synthetic materials, or a combination of both. They may provide a scaffold for cell growth, enhance tissue regeneration, and accelerate wound closure. Examples include acellular dermal matrices, cultured epidermal autografts, and bilayer bioengineered skin substitutes. For instance, the introduction of InnovaMatrix PD by Triad Life Sciences company is an innovative advancement in the management of wounds. 

The market also offers growth opportunities to the key players in the market. Emerging markets, including countries in Asia-Pacific, Latin America, and Africa, have experienced rapid economic growth, owing to increased healthcare spending, and surged demand for healthcare products and services. These factors drive the growth of the wound care biologics market in these regions.  In addition, emerging markets often experience diabetes and obesity. These chronic diseases contribute to the development of chronic wounds, which require specialized wound care treatments. Thus, the surge in prevalence of chronic diseases provides a lucrative opportunity for market growth. 

The wound care biologics market is segmented into product, wound type, end user and region. On the basis of drug class, the market is categorized into biological skin substitutes and topical agents. The biological skin substitutes segment further classified into human donor tissue derived products, animal derived products, and cell based bioengineered products. On the basis of wound type, the market is categorized into acute and chronic. The acute segment is further classified into burns & trauma, and surgical. The chronic segment is further divided into pressure ulcers, diabetic ulcers, venous ulcers, and others. 

On the basis of distribution channel, it is segregated into end user, the market is segregated into hospitals and clinics, wound centers and burn centers, and others. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific ((Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). 

The key players profiled in the study include ConvaTec Group plc, Integra LifeSciences Holdings Corporation, Kerecis, Lavior Pharma Inc., MIMEDX Group, Inc., Organogenesis Holding Inc., Skye Biologics Holdings, LLC, Smith & Nephew plc, Stryker Corporation., Tissue Regenix Group Plc. The players in the market have been actively engaged in the adoption various strategies such as a product launch, product approval, and acquisition to remain competitive and gain advantage over the competitors in the market. For instance, in December 2022, MiMedx Group, Inc., a leader in placental biologics announced agreement with Turn Therapeutics. This agreement provides MIMEDX with exclusive rights to Turn's PermaFusion proprietary antimicrobial intellectual property (IP) and utilize the PermaFusion platform in the development of future biologic products, with a specific focus on applications related to wound healing and surgical recovery.

Key Market Insights 

By product, the biological skin substitutes segment was the largest revenue contributor to the market and is estimated to reach $2,801.62 million by 2032, with a highest CAGR of 6.3%. 

By wound type, the chronic wound segment dominated the global market with a highest CAGR of 6.3% during the forecast period. 

Based on end user, the hospitals and clinics segment was the largest revenue contributor to the market and with a highest CAGR of 6.7% during the forecast period.   

Based on region, North America garnered the largest revenue share in 2022, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

Overview

The wound care biologics market was valued at $1.8 billion in 2022 and is estimated to reach $3.3 billion by 2032, exhibiting a CAGR of 6.1% from 2023 to 2032. Wound care biologics refers to a category of advanced medical products that are derived from biological sources or manufactured using biotechnology processes. These wound care biologics products are designed for healing and management of various types of wounds, such as acute and chronic wounds. In addition, wound care biologics products consist of extracellular matrix, growth factors, cellular components, or skin substitutes that mimic or supplement the body's natural healing processes. Biologic products such as biological skin substitutes and topical agents are used in the wound healing process by tissue regeneration and by reducing inflammation.

The wound care biologics market has experienced significant growth owing to the increase in prevalence of chronic wounds, such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers, which is a major factor that fosters the wound care biologics market growth. For instance, according to National Diabetes Statistics Report by Centers for Disease Control and Prevention (CDC), 2022, about 37.3 million people are diabetic in the U.S. As the number of people with diabetes continues to grow, so does the risk of developing diabetic foot ulcers, leading to higher demand for effective treatment options including wound care biologics. 

In addition, elderly individuals are more prone to chronic wounds thus, the rise in geriatric population drives the demand for wound care biologics and propels market growth. These advanced therapies provide efficient wound healing to this vulnerable population. Moreover, traditional wound care products such as hydrocolloids, hydrogels, film & foam dressings, and alginates are being increasingly replaced with advanced wound care products such as biologics, due to their enhanced effectiveness in managing wounds by enabling rapid healing, which further supports the market growth. 

Furthermore, research and development efforts have led to the introduction of innovative wound care biologics with enhanced efficacy and safety profiles. The introduction of novel growth factors, stem cell-based therapies, and tissue-engineered products have expanded the treatment options available, driving market growth. For instance, Organogenesis Holding Inc. company has developed and commercialized a product called Apligraf, which is an advanced tissue-engineered therapy designed for the treatment of chronic wounds. Such advanced products available in the market drive the market growth.  

In addition, ongoing research in the field of regenerative medicine, exploring the potential of stem cells, growth factors, and tissue engineering to promote wound healing further support the market growth This surge in investment in research and development activities by pharmaceutical companies, academic institutions, and healthcare organizations has accelerated the discovery of novel therapeutic approaches, fueling the growth of the market.   

The wound care biologics market is segmented on the basis of product, wound type, end user, and region. By product, the market is bifurcated into biological skin substitutes and topical agents. The biological skin substitutes segment further classified into human donor tissue derived products, animal derived products, and cell based bioengineered products. By wound type, the market is categorized into acute and chronic. The acute segment is further classified into burns & trauma, and surgical. The chronic segment is further divided into pressure ulcers, diabetic ulcers, venous ulcers, and others. By end user, the market is segregated into hospitals and clinics, wound centers and burn centers, and others. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA). 

Major key players that operate in the wound care biologics market are ConvaTec Group plc, Integra LifeSciences Holdings Corporation, Kerecis, Lavior Pharma Inc., MIMEDX Group, Inc., Organogenesis Holding Inc., Skye Biologics Holdings, LLC, Smith & Nephew plc, Stryker Corporation., Tissue Regenix Group Plc. Key players have adopted product launch, product approval, and acquisition as key developmental strategies to improve the product portfolio of the wound care biologics market. 

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the wound care biologics market analysis from 2022 to 2032 to identify the prevailing wound care biologics market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the wound care biologics market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global wound care biologics market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

● Quarterly Update and* (only available with a corporate license, on listed price)

● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.

● Free Upcoming Version on the Purchase of Five and Enterprise User License.

● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)

● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)

● Free data Pack on the Five and Enterprise User License. (Excel version of the report)

● Free Updated report if the report is 6-12 months old or older.

● 24-hour priority response*

● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)

● Regulatory Guidelines

● Additional company profiles with specific to client's interest

● Additional country or region analysis- market size and forecast

● Expanded list for Company Profiles

● Historic market data

● Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

○ ConvaTec Group pl

Scope of Wound Care Biologics Market Report

1.1. Report description

1.2. Key market segments

1.3. Key benefits to the stakeholders

1.4. Research Methodology

1.4.1. Primary research

1.4.2. Secondary research

1.4.3. Analyst tools and models

2.1. CXO Perspective

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top impacting factors

3.2.2. Top investment pockets

3.3. Porter’s five forces analysis

3.3.1. Moderate bargaining power of suppliers

3.3.2. Moderate threat of new entrants

3.3.3. Moderate threat of substitutes

3.3.4. Moderate intensity of rivalry

3.3.5. Moderate bargaining power of buyers

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Growing burden of burn injuries and road accidents

3.4.1.2. Surge in incidences of chronic diseases and surgeries

3.4.1.3. Advancements in wound care management

3.4.2. Restraints

3.4.2.1. High cost of wound care biologics

3.4.2.2. Stringent regulations for manufacturing of wound care products

3.4.3. Opportunities

3.4.3.1. Growth opportunities in emerging markets

3.5. COVID-19 Impact Analysis on the market

4.1. Overview

4.1.1. Market size and forecast

4.2. Biological Skin Substitutes

4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market share analysis by country

4.2.4. Biological Skin Substitutes Wound Care Biologics Market by Type

4.3. Topical Agents

4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market share analysis by country

5.1. Overview

5.1.1. Market size and forecast

5.2. Acute Wound

5.2.1. Key market trends, growth factors and opportunities

5.2.2. Market size and forecast, by region

5.2.3. Market share analysis by country

5.2.4. Acute Wound Wound Care Biologics Market by Type

5.3. Chronic Wound

5.3.1. Key market trends, growth factors and opportunities

5.3.2. Market size and forecast, by region

5.3.3. Market share analysis by country

5.3.4. Chronic Wound Wound Care Biologics Market by Type

6.1. Overview

6.1.1. Market size and forecast

6.2. Hospitals and Clinics

6.2.1. Key market trends, growth factors and opportunities

6.2.2. Market size and forecast, by region

6.2.3. Market share analysis by country

6.3. Wound Centers and Burn Centers

6.3.1. Key market trends, growth factors and opportunities

6.3.2. Market size and forecast, by region

6.3.3. Market share analysis by country

6.4. Others

6.4.1. Key market trends, growth factors and opportunities

6.4.2. Market size and forecast, by region

6.4.3. Market share analysis by country

7.1. Overview

7.1.1. Market size and forecast By Region

7.2. North America

7.2.1. Key trends and opportunities

7.2.2. Market size and forecast, by Product

7.2.3. Market size and forecast, by Wound Type

7.2.4. Market size and forecast, by End User

7.2.5. Market size and forecast, by country

7.2.5.1. U.S.

7.2.5.1.1. Key market trends, growth factors and opportunities

7.2.5.1.2. Market size and forecast, by Product

7.2.5.1.3. Market size and forecast, by Wound Type

7.2.5.1.4. Market size and forecast, by End User

7.2.5.2. Canada

7.2.5.2.1. Key market trends, growth factors and opportunities

7.2.5.2.2. Market size and forecast, by Product

7.2.5.2.3. Market size and forecast, by Wound Type

7.2.5.2.4. Market size and forecast, by End User

7.2.5.3. Mexico

7.2.5.3.1. Key market trends, growth factors and opportunities

7.2.5.3.2. Market size and forecast, by Product

7.2.5.3.3. Market size and forecast, by Wound Type

7.2.5.3.4. Market size and forecast, by End User

7.3. Europe

7.3.1. Key trends and opportunities

7.3.2. Market size and forecast, by Product

7.3.3. Market size and forecast, by Wound Type

7.3.4. Market size and forecast, by End User

7.3.5. Market size and forecast, by country

7.3.5.1. Germany

7.3.5.1.1. Key market trends, growth factors and opportunities

7.3.5.1.2. Market size and forecast, by Product

7.3.5.1.3. Market size and forecast, by Wound Type

7.3.5.1.4. Market size and forecast, by End User

7.3.5.2. France

7.3.5.2.1. Key market trends, growth factors and opportunities

7.3.5.2.2. Market size and forecast, by Product

7.3.5.2.3. Market size and forecast, by Wound Type

7.3.5.2.4. Market size and forecast, by End User

7.3.5.3. UK

7.3.5.3.1. Key market trends, growth factors and opportunities

7.3.5.3.2. Market size and forecast, by Product

7.3.5.3.3. Market size and forecast, by Wound Type

7.3.5.3.4. Market size and forecast, by End User

7.3.5.4. Italy

7.3.5.4.1. Key market trends, growth factors and opportunities

7.3.5.4.2. Market size and forecast, by Product

7.3.5.4.3. Market size and forecast, by Wound Type

7.3.5.4.4. Market size and forecast, by End User

7.3.5.5. Spain

7.3.5.5.1. Key market trends, growth factors and opportunities

7.3.5.5.2. Market size and forecast, by Product

7.3.5.5.3. Market size and forecast, by Wound Type

7.3.5.5.4. Market size and forecast, by End User

7.3.5.6. Rest of Europe

7.3.5.6.1. Key market trends, growth factors and opportunities

7.3.5.6.2. Market size and forecast, by Product

7.3.5.6.3. Market size and forecast, by Wound Type

7.3.5.6.4. Market size and forecast, by End User

7.4. Asia-Pacific

7.4.1. Key trends and opportunities

7.4.2. Market size and forecast, by Product

7.4.3. Market size and forecast, by Wound Type

7.4.4. Market size and forecast, by End User

7.4.5. Market size and forecast, by country

7.4.5.1. Japan

7.4.5.1.1. Key market trends, growth factors and opportunities

7.4.5.1.2. Market size and forecast, by Product

7.4.5.1.3. Market size and forecast, by Wound Type

7.4.5.1.4. Market size and forecast, by End User

7.4.5.2. China

7.4.5.2.1. Key market trends, growth factors and opportunities

7.4.5.2.2. Market size and forecast, by Product

7.4.5.2.3. Market size and forecast, by Wound Type

7.4.5.2.4. Market size and forecast, by End User

7.4.5.3. India

7.4.5.3.1. Key market trends, growth factors and opportunities

7.4.5.3.2. Market size and forecast, by Product

7.4.5.3.3. Market size and forecast, by Wound Type

7.4.5.3.4. Market size and forecast, by End User

7.4.5.4. Australia

7.4.5.4.1. Key market trends, growth factors and opportunities

7.4.5.4.2. Market size and forecast, by Product

7.4.5.4.3. Market size and forecast, by Wound Type

7.4.5.4.4. Market size and forecast, by End User

7.4.5.5. South Korea

7.4.5.5.1. Key market trends, growth factors and opportunities

7.4.5.5.2. Market size and forecast, by Product

7.4.5.5.3. Market size and forecast, by Wound Type

7.4.5.5.4. Market size and forecast, by End User

7.4.5.6. Rest of Asia-Pacific

7.4.5.6.1. Key market trends, growth factors and opportunities

7.4.5.6.2. Market size and forecast, by Product

7.4.5.6.3. Market size and forecast, by Wound Type

7.4.5.6.4. Market size and forecast, by End User

7.5. LAMEA

7.5.1. Key trends and opportunities

7.5.2. Market size and forecast, by Product

7.5.3. Market size and forecast, by Wound Type

7.5.4. Market size and forecast, by End User

7.5.5. Market size and forecast, by country

7.5.5.1. Brazil

7.5.5.1.1. Key market trends, growth factors and opportunities

7.5.5.1.2. Market size and forecast, by Product

7.5.5.1.3. Market size and forecast, by Wound Type

7.5.5.1.4. Market size and forecast, by End User

7.5.5.2. Saudi Arabia

7.5.5.2.1. Key market trends, growth factors and opportunities

7.5.5.2.2. Market size and forecast, by Product

7.5.5.2.3. Market size and forecast, by Wound Type

7.5.5.2.4. Market size and forecast, by End User

7.5.5.3. South Africa

7.5.5.3.1. Key market trends, growth factors and opportunities

7.5.5.3.2. Market size and forecast, by Product

7.5.5.3.3. Market size and forecast, by Wound Type

7.5.5.3.4. Market size and forecast, by End User

7.5.5.4. Rest of LAMEA

7.5.5.4.1. Key market trends, growth factors and opportunities

7.5.5.4.2. Market size and forecast, by Product

7.5.5.4.3. Market size and forecast, by Wound Type

7.5.5.4.4. Market size and forecast, by End User

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Top player positioning, 2022

9.1. Integra LifeSciences Holdings Corporation

9.1.1. Company overview

9.1.2. Key Executives

9.1.3. Company snapshot

9.1.4. Operating business segments

9.1.5. Product portfolio

9.1.6. Business performance

9.2. Kerecis

9.2.1. Company overview

9.2.2. Key Executives

9.2.3. Company snapshot

9.2.4. Operating business segments

9.2.5. Product portfolio

9.3. MIMEDX Group, Inc.

9.3.1. Company overview

9.3.2. Key Executives

9.3.3. Company snapshot

9.3.4. Operating business segments

9.3.5. Product portfolio

9.3.6. Business performance

9.3.7. Key strategic moves and developments

9.4. ORGANOGENESIS HOLDINGS INC.

9.4.1. Company overview

9.4.2. Key Executives

9.4.3. Company snapshot

9.4.4. Operating business segments

9.4.5. Product portfolio

9.4.6. Business performance

9.5. Skye Biologics Holdings, LLC

9.5.1. Company overview

9.5.2. Key Executives

9.5.3. Company snapshot

9.5.4. Operating business segments

9.5.5. Product portfolio

9.6. Smith & Nephew plc

9.6.1. Company overview

9.6.2. Key Executives

9.6.3. Company snapshot

9.6.4. Operating business segments

9.6.5. Product portfolio

9.6.6. Business performance

9.7. Stryker Corporation.

9.7.1. Company overview

9.7.2. Key Executives

9.7.3. Company snapshot

9.7.4. Operating business segments

9.7.5. Product portfolio

9.7.6. Business performance

9.7.7. Key strategic moves and developments

9.8. Tissue Regenix Group Plc

9.8.1. Company overview

9.8.2. Key Executives

9.8.3. Company snapshot

9.8.4. Operating business segments

9.8.5. Product portfolio

9.8.6. Business performance

9.9. ConvaTec Group plc

9.9.1. Company overview

9.9.2. Key Executives

9.9.3. Company snapshot

9.9.4. Operating business segments

9.9.5. Product portfolio

9.9.6. Business performance

9.9.7. Key strategic moves and developments

9.10. Lavior Pharma Inc.

9.10.1. Company overview

9.10.2. Key Executives

9.10.3. Company snapshot

9.10.4. Operating business segments

9.10.5. Product portfoli

LIST OF TABLES

TABLE 01. GLOBAL WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 02. WOUND CARE BIOLOGICS MARKET FOR BIOLOGICAL SKIN SUBSTITUTES, BY REGION, 2022-2032 ($MILLION)

TABLE 03. GLOBAL BIOLOGICAL SKIN SUBSTITUTES WOUND CARE BIOLOGICS MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 04. WOUND CARE BIOLOGICS MARKET FOR TOPICAL AGENTS, BY REGION, 2022-2032 ($MILLION)

TABLE 05. GLOBAL WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)

TABLE 06. WOUND CARE BIOLOGICS MARKET FOR ACUTE WOUND, BY REGION, 2022-2032 ($MILLION)

TABLE 07. GLOBAL ACUTE WOUND WOUND CARE BIOLOGICS MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 08. WOUND CARE BIOLOGICS MARKET FOR CHRONIC WOUND, BY REGION, 2022-2032 ($MILLION)

TABLE 09. GLOBAL CHRONIC WOUND WOUND CARE BIOLOGICS MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 10. GLOBAL WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 11. WOUND CARE BIOLOGICS MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2022-2032 ($MILLION)

TABLE 12. WOUND CARE BIOLOGICS MARKET FOR WOUND CENTERS AND BURN CENTERS, BY REGION, 2022-2032 ($MILLION)

TABLE 13. WOUND CARE BIOLOGICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)

TABLE 14. WOUND CARE BIOLOGICS MARKET, BY REGION, 2022-2032 ($MILLION)

TABLE 15. NORTH AMERICA WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 16. NORTH AMERICA WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)

TABLE 17. NORTH AMERICA WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 18. NORTH AMERICA WOUND CARE BIOLOGICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 19. U.S. WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 20. U.S. WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)

TABLE 21. U.S. WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 22. CANADA WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 23. CANADA WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)

TABLE 24. CANADA WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 25. MEXICO WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 26. MEXICO WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)

TABLE 27. MEXICO WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 28. EUROPE WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 29. EUROPE WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)

TABLE 30. EUROPE WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 31. EUROPE WOUND CARE BIOLOGICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 32. GERMANY WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 33. GERMANY WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)

TABLE 34. GERMANY WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 35. FRANCE WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 36. FRANCE WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)

TABLE 37. FRANCE WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 38. UK WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 39. UK WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)

TABLE 40. UK WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 41. ITALY WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 42. ITALY WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)

TABLE 43. ITALY WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 44. SPAIN WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 45. SPAIN WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)

TABLE 46. SPAIN WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 47. REST OF EUROPE WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 48. REST OF EUROPE WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)

TABLE 49. REST OF EUROPE WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 50. ASIA-PACIFIC WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 51. ASIA-PACIFIC WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)

TABLE 52. ASIA-PACIFIC WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 53. ASIA-PACIFIC WOUND CARE BIOLOGICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 54. JAPAN WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 55. JAPAN WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)

TABLE 56. JAPAN WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 57. CHINA WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 58. CHINA WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)

TABLE 59. CHINA WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 60. INDIA WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 61. INDIA WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)

TABLE 62. INDIA WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 63. AUSTRALIA WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 64. AUSTRALIA WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)

TABLE 65. AUSTRALIA WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 66. SOUTH KOREA WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 67. SOUTH KOREA WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)

TABLE 68. SOUTH KOREA WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 69. REST OF ASIA-PACIFIC WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 70. REST OF ASIA-PACIFIC WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)

TABLE 71. REST OF ASIA-PACIFIC WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 72. LAMEA WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 73. LAMEA WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)

TABLE 74. LAMEA WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 75. LAMEA WOUND CARE BIOLOGICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 76. BRAZIL WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 77. BRAZIL WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)

TABLE 78. BRAZIL WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 79. SAUDI ARABIA WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 80. SAUDI ARABIA WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)

TABLE 81. SAUDI ARABIA WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 82. SOUTH AFRICA WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 83. SOUTH AFRICA WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)

TABLE 84. SOUTH AFRICA WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 85. REST OF LAMEA WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 86. REST OF LAMEA WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)

TABLE 87. REST OF LAMEA WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 88. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: KEY EXECUTIVES

TABLE 89. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: COMPANY SNAPSHOT

TABLE 90. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: PRODUCT SEGMENTS

TABLE 91. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: PRODUCT PORTFOLIO

TABLE 92. KERECIS: KEY EXECUTIVES

TABLE 93. KERECIS: COMPANY SNAPSHOT

TABLE 94. KERECIS: PRODUCT SEGMENTS

TABLE 95. KERECIS: PRODUCT PORTFOLIO

TABLE 96. MIMEDX GROUP, INC.: KEY EXECUTIVES

TABLE 97. MIMEDX GROUP, INC.: COMPANY SNAPSHOT

TABLE 98. MIMEDX GROUP, INC.: PRODUCT SEGMENTS

TABLE 99. MIMEDX GROUP, INC.: PRODUCT PORTFOLIO

TABLE 100. MIMEDX GROUP, INC.: KEY STRATERGIES

TABLE 101. ORGANOGENESIS HOLDINGS INC.: KEY EXECUTIVES

TABLE 102. ORGANOGENESIS HOLDINGS INC.: COMPANY SNAPSHOT

TABLE 103. ORGANOGENESIS HOLDINGS INC.: PRODUCT SEGMENTS

TABLE 104. ORGANOGENESIS HOLDINGS INC.: PRODUCT PORTFOLIO

TABLE 105. SKYE BIOLOGICS HOLDINGS, LLC: KEY EXECUTIVES

TABLE 106. SKYE BIOLOGICS HOLDINGS, LLC: COMPANY SNAPSHOT

TABLE 107. SKYE BIOLOGICS HOLDINGS, LLC: PRODUCT SEGMENTS

TABLE 108. SKYE BIOLOGICS HOLDINGS, LLC: PRODUCT PORTFOLIO

TABLE 109. SMITH & NEPHEW PLC: KEY EXECUTIVES

TABLE 110. SMITH & NEPHEW PLC: COMPANY SNAPSHOT

TABLE 111. SMITH & NEPHEW PLC: PRODUCT SEGMENTS

TABLE 112. SMITH & NEPHEW PLC: PRODUCT PORTFOLIO

TABLE 113. STRYKER CORPORATION.: KEY EXECUTIVES

TABLE 114. STRYKER CORPORATION.: COMPANY SNAPSHOT

TABLE 115. STRYKER CORPORATION.: PRODUCT SEGMENTS

TABLE 116. STRYKER CORPORATION.: PRODUCT PORTFOLIO

TABLE 117. STRYKER CORPORATION.: KEY STRATERGIES

TABLE 118. TISSUE REGENIX GROUP PLC: KEY EXECUTIVES

TABLE 119. TISSUE REGENIX GROUP PLC: COMPANY SNAPSHOT

TABLE 120. TISSUE REGENIX GROUP PLC: PRODUCT SEGMENTS

TABLE 121. TISSUE REGENIX GROUP PLC: PRODUCT PORTFOLIO

TABLE 122. CONVATEC GROUP PLC: KEY EXECUTIVES

TABLE 123. CONVATEC GROUP PLC: COMPANY SNAPSHOT

TABLE 124. CONVATEC GROUP PLC: PRODUCT SEGMENTS

TABLE 125. CONVATEC GROUP PLC: PRODUCT PORTFOLIO

TABLE 126. CONVATEC GROUP PLC: KEY STRATERGIES

TABLE 127. LAVIOR PHARMA INC.: KEY EXECUTIVES

TABLE 128. LAVIOR PHARMA INC.: COMPANY SNAPSHOT

TABLE 129. LAVIOR PHARMA INC.: PRODUCT SEGMENTS

TABLE 130. LAVIOR PHARMA INC.: PRODUCT PORTFOLIO LIST OF FIGURES

FIGURE 01. WOUND CARE BIOLOGICS MARKET, 2022-2032

FIGURE 02. SEGMENTATION OF WOUND CARE BIOLOGICS MARKET,2022-2032

FIGURE 03. TOP INVESTMENT POCKETS IN WOUND CARE BIOLOGICS MARKET (2023-2032)

FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS

FIGURE 05. MODERATE THREAT OF NEW ENTRANTS

FIGURE 06. MODERATE THREAT OF SUBSTITUTES

FIGURE 07. MODERATE INTENSITY OF RIVALRY

FIGURE 08. MODERATE BARGAINING POWER OF BUYERS

FIGURE 09. GLOBAL WOUND CARE BIOLOGICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 10. WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022(%)

FIGURE 11. COMPARATIVE SHARE ANALYSIS OF WOUND CARE BIOLOGICS MARKET FOR BIOLOGICAL SKIN SUBSTITUTES, BY COUNTRY 2022 AND 2032(%)

FIGURE 12. COMPARATIVE SHARE ANALYSIS OF WOUND CARE BIOLOGICS MARKET FOR TOPICAL AGENTS, BY COUNTRY 2022 AND 2032(%)

FIGURE 13. WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022(%)

FIGURE 14. COMPARATIVE SHARE ANALYSIS OF WOUND CARE BIOLOGICS MARKET FOR ACUTE WOUND, BY COUNTRY 2022 AND 2032(%)

FIGURE 15. COMPARATIVE SHARE ANALYSIS OF WOUND CARE BIOLOGICS MARKET FOR CHRONIC WOUND, BY COUNTRY 2022 AND 2032(%)

FIGURE 16. WOUND CARE BIOLOGICS MARKET, BY END USER, 2022(%)

FIGURE 17. COMPARATIVE SHARE ANALYSIS OF WOUND CARE BIOLOGICS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY 2022 AND 2032(%)

FIGURE 18. COMPARATIVE SHARE ANALYSIS OF WOUND CARE BIOLOGICS MARKET FOR WOUND CENTERS AND BURN CENTERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 19. COMPARATIVE SHARE ANALYSIS OF WOUND CARE BIOLOGICS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 20. WOUND CARE BIOLOGICS MARKET BY REGION, 2022(%)

FIGURE 21. U.S. WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)

FIGURE 22. CANADA WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)

FIGURE 23. MEXICO WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)

FIGURE 24. GERMANY WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)

FIGURE 25. FRANCE WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)

FIGURE 26. UK WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)

FIGURE 27. ITALY WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)

FIGURE 28. SPAIN WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)

FIGURE 29. REST OF EUROPE WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)

FIGURE 30. JAPAN WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)

FIGURE 31. CHINA WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)

FIGURE 32. INDIA WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)

FIGURE 33. AUSTRALIA WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)

FIGURE 34. SOUTH KOREA WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)

FIGURE 35. REST OF ASIA-PACIFIC WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)

FIGURE 36. BRAZIL WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)

FIGURE 37. SAUDI ARABIA WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)

FIGURE 38. SOUTH AFRICA WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)

FIGURE 39. REST OF LAMEA WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)

FIGURE 40. TOP WINNING STRATEGIES, BY YEAR

FIGURE 41. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 42. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 43. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 44. COMPETITIVE DASHBOARD

FIGURE 45. COMPETITIVE HEATMAP: WOUND CARE BIOLOGICS MARKET

FIGURE 46. TOP PLAYER POSITIONING, 2022

FIGURE 47. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 48. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 49. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 50. MIMEDX GROUP, INC.: NET SALES, 2020-2022 ($MILLION)

FIGURE 51. ORGANOGENESIS HOLDINGS INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 52. SMITH & NEPHEW PLC: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 53. SMITH & NEPHEW PLC: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 54. SMITH & NEPHEW PLC: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 55. STRYKER CORPORATION.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 56. STRYKER CORPORATION.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 57. STRYKER CORPORATION.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 58. TISSUE REGENIX GROUP PLC: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 59. TISSUE REGENIX GROUP PLC: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 60. CONVATEC GROUP PLC: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 61. CONVATEC GROUP PLC: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 62. CONVATEC GROUP PLC: REVENUE SHARE BY REGION, 2022 (%